By James Pearson
Publication Date: 2026-05-14 02:28:00
Presented by Bulls and bears
James Pearson
Australia’s biotechnology sector is quickly colliding with the explosive rise of artificial intelligence, and Perth-based Syngenis Laboratories wants to push itself into the middle of the revolution.
The company has developed an AI-powered discovery platform called Syngenis Discovery that is designed to dramatically accelerate the search for next-generation therapies and diagnostic molecules. In doing so, Syngenis aims to overcome one of the biggest bottlenecks in biotechnology – identifying viable treatments from billions of potential molecule combinations.
In traditional drug discovery, laboratory testing, modeling, sequence refinement, and toxicity analysis can take months or even years.
